Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort

Includes abstract.

Saved in:
Bibliographic Details
Main Author: Meyer, Jacqueline
Other Authors: Ramesar, Raj
Format: Thesis
Language:English
Published: Division of Human Genetics 2014
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613275310522368
access_status_str Open Access
author Meyer, Jacqueline
author2 Ramesar, Raj
author_browse Meyer, Jacqueline
Ramesar, Raj
author_facet Ramesar, Raj
Meyer, Jacqueline
author_sort Meyer, Jacqueline
collection Thesis
description Includes abstract.
format Thesis
id oai:open.uct.ac.za:11427/3099
institution University of Cape Town (South Africa)
language eng
last_indexed 2026-06-10T12:33:33.643Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository
publishDate 2014
publishDateRange 2014
publishDateSort 2014
publisher Division of Human Genetics
publisherStr Division of Human Genetics
record_format dspace
source_str UCTD — University of Cape Town Open Access Repository
spelling oai:open.uct.ac.za:11427/3099 Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort Meyer, Jacqueline Ramesar, Raj Medicine Includes abstract. Includes bibliographical references (leaves 106-120). To date, surgery is the mainstay treatment for HNPCC. Adjuvant chemotherapy and radiotherapy are often used to reduce systemic and locoregional recurrence, respectively, after curative surgical resection. The main chemotherapeutic agent is 5-Fluoroucacil (5-FU). Studies have attempted to elucidate whether the MMR status of a colorectal cancer (CRC) cohort will define a response to 5-FU therapy. However, no difference in long term response or survival after 5-FU treatment between patients with MMR-proficient and MMR-deficient tomours were detected. 2014-07-28T14:52:31Z 2014-07-28T14:52:31Z 2009 Master Thesis Masters MSc http://hdl.handle.net/11427/3099 eng application/pdf Division of Human Genetics Faculty of Health Sciences University of Cape Town
spellingShingle Medicine
Meyer, Jacqueline
Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort
thesis_degree_str Master's
title Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort
title_full Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort
title_fullStr Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort
title_full_unstemmed Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort
title_short Pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5-Fluorouracil in a South African colorectal cancer cohort
title_sort pharmacogenomic profiling and clarification of the role of the mismatch repair genes in response to the chemotherapeutic agent 5 fluorouracil in a south african colorectal cancer cohort
topic Medicine
url http://hdl.handle.net/11427/3099
work_keys_str_mv AT meyerjacqueline pharmacogenomicprofilingandclarificationoftheroleofthemismatchrepairgenesinresponsetothechemotherapeuticagent5fluorouracilinasouthafricancolorectalcancercohort